

Claims

1. A crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, characterized by:
 - a. the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 4.7°, 14.1°, and 20.1°; or
 - b. the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 12.8°, 18.0°, and 18.3°.
2. A crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide according to claim 1, characterized by
 - a. the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 4.7°, 9.3°, 14.1°, 20.1°, and 24.7°; or
 - b. the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 12.4°, 12.8°, 15.7°, 18.0°, and 18.3°.
3. A crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 4.7°, 14.1°, and 20.1°.
4. A crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 4.7°, 9.3°, 12.0°, 14.1°, 16.3°, 18.4°, 20.1°, 21.8°, 24.7°, and 28.6°.
5. A crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 12.8°, 18.0°, and 18.3°.
6. A crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 10.9°, 12.4°, 12.8°, 13.2°, 15.7°, 16.3°, 18.0°, 18.3°, 21.1°, and 29.3°.
7. A crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, characterized by the presence of peaks in

the X-ray powder diffraction diagram at the following angles of refraction 2θ : 4.70, 14.1, and 20.1, obtainable by:

- a. heating a suspension comprising *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide in about 5 vol. toluene at reflux until dissolution;
- b. cooling of the solution to about 25 °C within 1 to 5 hours;
- c. cooling to 0 °C; and
- d. isolating of the obtained solid residue.

8. A pharmaceutical composition comprising as active ingredient a crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide according to claim 1, and at least one pharmaceutically acceptable carrier.

9. Use of a crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide according to claim 1, in the manufacture of a medicament for the prevention and/or treatment of a disease or disorder selected from epilepsy; sleep disorders; sleep disturbances; pain selected from inflammatory pain, neuropathic pain, peripheral pain, and chronic pain associated with peripheral axonal injury; neurological disorders selected from essential tremors, Parkinson's disease, schizophrenia, depression, anxiety, psychosis, neurodegenerative disorders, autism and drug addiction; cardiovascular disorders selected from hypertension, cardiac arrhythmias, atrial fibrillation, congenital heart failure and heart block; cancer; diabetes; and diabetic neuropathy.

10. Use of a crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide according to claim 1, in the manufacture of a medicament for the prevention and/or treatment of epilepsy.

11. The use according to claim 9, wherein the crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide is characterized by

- a. the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 4.7°, 9.3°, 14.1°, 20.1°, and 24.7°; or
- b. the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 12.4°, 12.8°, 15.7°, 18.0°, and 18.3°.

12. The use according to claim 10, wherein the crystalline form of *N*-[1-(5-cyano-pyridin-2-ylmethyl)-1*H*-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide is characterized by

- a. the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 4.7°, 9.3°, 14.1°, 20.1°, and 24.7°; or
- b. the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ : 12.4°, 12.8°, 15.7°, 18.0°, and 18.3°.